CDK1 and glioblastoma: In addition, we showed that CDK1/PBK/CHEK1 overexpression promotes GBM tumor aggressiveness, immunosuppression, and progression by recruiting the tumor-promoting immune cells such as the T Cells CD4+ Th2 subtype, MDSCs, and the TAM-M2 subtype [42,46,53,54].